This tab maps the IP landscape and names legal frameworks. It does not prescribe what Indigenous regulatory design should look like.
Scoring Rubric
What FPIC Requires in Practice
Who gives consent: FPIC must be obtained from the relevant community through its own decision-making processes — not from individual community members, not from government representatives, and not from self-appointed spokespeople. For Mazatec communities, this means the traditional Mazatec governance structures. For Bwiti communities, this means Bwiti leadership. For Native American Church, this means NAC leadership.
Binding vs aspirational: The critical distinction is between aspirational statements (press releases, website commitments, ESG reports) and legally binding agreements (contracts, trust structures, regulatory conditions). Journey Colab's Reciprocity Trust is legally binding — 5% of equity is structurally committed, not aspirationally promised. Every other psychedelic company's benefit-sharing language is aspirational.
Synthetic vs Plant-Based: How Nagoya Applies
The issue: Nagoya Protocol covers genetic resources and associated traditional knowledge. The 'genetic resources' covered include plant-based compounds — iboga, psilocybin mushrooms, ayahuasca plants, peyote cacti. Synthetic compounds produced without using the biological resource may fall outside Nagoya's scope.
Implication: Companies producing synthetic psilocybin (Compass COMP360), synthetic 5-MeO-DMT (GH Research's claimed synthetic GH001), and synthetic ibogaine (DemeRx) may argue they are not using genetic resources and therefore Nagoya does not apply — even though their products are derived from knowledge of compounds that originated in Indigenous communities.
Counter-argument: Nagoya also covers 'traditional knowledge associated with genetic resources.' The pharmacological knowledge — that psilocybin produces therapeutic effects, that ibogaine interrupts addiction, that 5-MeO-DMT produces mystical states — is traditional knowledge even when the compound is synthesised. Whether this interpretation is legally enforced depends on jurisdiction and political will.
Monitor: Any legal case or regulatory decision that clarifies whether synthetic psychedelic production triggers Nagoya or equivalent ABS obligations is a primary refresh trigger for this tab.
Positive Models
Reciprocity Trust — 5% of equity set aside for benefit-sharing with Indigenous communities whose traditional knowledge contributed to the company's work. Legally structured as trust, not aspirational statement.
Most substantive legally binding benefit-sharing commitment in the psychedelic sector as of mid-2026. Monitor for implementation and distribution.
Chacruna Institute Ethical Guidelines
- Cultural attribution requirements: practitioners must acknowledge the Indigenous origins of plant medicines they work with
- Anti-appropriation standards: distinguishing respectful engagement from extractive appropriation
- Community benefit obligations: practitioners working with Indigenous plant medicines should direct benefit back to originating communities
- FPIC as professional standard: genuine consent from Indigenous knowledge holders before incorporating their practices
- Opposition to biopiracy: explicit stance against patenting or commercialising Indigenous knowledge without consent and benefit-sharing
Status: Voluntary professional guidelines. Not legally binding. Adoption by Oregon or Colorado licensed facilitators is not tracked by state regulatory bodies — a significant gap.
Significance: The Chacruna guidelines represent emerging professional standards that could be embedded in state facilitator licensing requirements. Currently, no US psychedelic jurisdiction requires facilitators to adhere to any Indigenous knowledge protection standards.
Documented Cases
R. Gordon Wasson's 1957 Life magazine article 'Seeking the Magic Mushroom' introduced psilocybin mushrooms to Western discourse. Wasson participated in a Mazatec velada ceremony guided by María Sabina without her informed consent regarding publication. The article named her and her village, ending her traditional practice and exposing her community to unwanted attention.
Outcome: Mazatec community has not benefited from any resulting commercial patent applications or the $billions in psychedelic sector investment that traces directly to Wasson's 1957 extraction. María Sabina's life was destroyed — her home burned, she died in poverty. The Mazatec velada tradition has not been compensated, credited, or included in regulatory design of markets built on knowledge first commercialised through her ceremony.
Legal status: No benefit-sharing agreement exists between any psychedelic company and the Mazatec community as of mid-2026.
Gabon restricted iboga export in 2019 under Law No. 002/2019, classifying iboga as a national patrimony. The restriction was a direct response to commercial extraction pressure from Western ibogaine therapy companies and research institutions.
Outcome: Commercial ibogaine development (MindMed, atai/DemeRx, MAPS-adjacent research) proceeds without benefit-sharing frameworks with Gabonese or Cameroonian Bwiti communities. MindMed's ibogaine program (MM-18) does not document Bwiti consultation. The export restriction provides partial protection but does not address synthetic ibogaine production, which is proceeding independently.
Legal status: Gabon Law No. 002/2019 restricts export but does not create benefit-sharing mechanism. No FPIC consultation documented by any commercial ibogaine developer.
Amazonian communities developed and refined the DMT/MAOI pharmacological combination knowledge over centuries. The specific knowledge that combining Banisteriopsis caapi vine (MAOI) with Psychotria viridis (DMT) creates oral bioavailability of DMT — when DMT alone is not orally active — is a profound pharmacological discovery. Western researchers patented derivatives without attribution.
Outcome: Multiple patent applications implicate ayahuasca pharmacology without attribution or benefit-sharing. The US Patent and Trademark Office granted US Patent 5,751,517 on ayahuasca (B. caapi) in 1986 — later challenged and narrowed but not fully revoked. DMT and MAOI combination approaches are being independently patented by Western pharmaceutical companies.
Legal status: No binding benefit-sharing framework exists between any commercial entity and Amazonian communities for DMT/MAOI development. COICA (Coordinator of Indigenous Organizations of the Amazon River Basin) has formally opposed commercialisation without consent.
Colorado Proposition 122 (2022) decriminalised peyote personal use but simultaneously covered synthetic mescaline production and distribution. The NAC specifically requested peyote exclusion from commercial frameworks — Colorado complied with the exclusion of peyote but not with synthetic mescaline, which is a direct pharmacological derivative.
Outcome: Synthetic mescaline production and distribution is now legal in Colorado without any consultation with or benefit-sharing with the Wixaritari, who hold primary knowledge of mescaline's ceremonial use. The legal synthetic mescaline market is being built on knowledge embedded in NAC and Wixaritari traditions without their involvement.
Legal status: Colorado excluded peyote by name from Prop 122 but did not extend that exclusion to synthetic mescaline. No FPIC consultation with Wixaritari documented for synthetic mescaline commercial development.
5-MeO-DMT extracted from Bufo alvarius toad venom has become a commercial retreat and research compound. GH Research (GHRS) is pursuing pharmaceutical development of inhaled 5-MeO-DMT. The toad is facing population pressure from extraction for venom. The Yaqui people of Sonora have documented historical knowledge of the toad's ceremonial significance.
Outcome: GH Research claims its GH001 product uses synthetic 5-MeO-DMT — but no independent verification of supply chain at commercial scale has been published. The Sonoran Desert toad population is under documented stress. No benefit-sharing framework with Yaqui or Seri peoples has been documented by any commercial 5-MeO-DMT developer.
Legal status: No protected status for Bufo alvarius under CITES. No FPIC framework for Yaqui or Seri peoples in any commercial 5-MeO-DMT development.
Legal Frameworks
Supplementary agreement to the Convention on Biological Diversity (CBD). 137 parties as of 2024.
Structural gap: the three jurisdictions with the most active psychedelic commercialisation have not ratified Nagoya. This means companies operating in these jurisdictions have no binding ABS obligations under international law, even when they commercialise knowledge derived from Indigenous communities in Nagoya-party countries.
Psilocybin, ibogaine, ayahuasca compounds, and 5-MeO-DMT all implicate traditional knowledge from biodiversity-rich regions. Nagoya's Access and Benefit Sharing (ABS) provisions would require prior informed consent and equitable benefit sharing for commercial use of this knowledge — but only in jurisdictions that have ratified.
Non-adopters in active psychedelic jurisdictions: United States, Canada, Australia
Free, Prior and Informed Consent (FPIC) — Article 19 requires states to consult and cooperate in good faith with Indigenous peoples to obtain their FPIC before adopting legislative or administrative measures that may affect them
Non-binding declaration — but normative weight is significant. Monitor for binding implementation in state-level psychedelic frameworks. Colombia 2021 bill is the only example of FPIC-style provision in a psychedelic regulatory instrument.
US voted against UNDRIP in 2007; endorsed in 2010 with reservations. FPIC provisions have not been implemented in any US psychedelic regulatory framework.
Sponsor: Senator Senator Ivan Marulanda
Directly inspired by How to Regulate Stimulants (Transform, 2020). First national legislature to use a Transform-derived framework as a drafting reference.
FPIC-style prior consultation with Indigenous authorities built into licensing framework for coca cultivation and processing
Positive model — first Transform-framework-inspired legislation to operationalise Indigenous rights protection in a drug regulatory instrument
The pattern across five documented cases is consistent: Western commercial interests extract pharmacological knowledge embedded in Indigenous communities, commercialise it without consultation or benefit-sharing, and regulatory frameworks are designed without FPIC provisions because the jurisdictions where commercialisation is most active (US, Canada, Australia) have not ratified Nagoya. This is not incidental — it is structural. The absence of Nagoya ratification in the three most active psychedelic commercial jurisdictions is the legal gap that makes extraction without consequence possible.
The synthetic/plant-based distinction matters for legal analysis but not for ethical analysis. A company producing synthetic 5-MeO-DMT or synthetic ibogaine may argue it is not using genetic resources under Nagoya. But the pharmacological knowledge — that these compounds produce therapeutic effects — is traditional knowledge whether the compound is extracted or synthesised. The Chacruna guidelines represent the emerging professional standard; no US licensing regime requires adherence to them. This is the gap between aspiration and structural requirement.
The implications compound with Tab 2 (Patents). The same IP strategies that enclose access for US users also enclose the commercial benefit of knowledge that originated in Mazatec, Bwiti, Amazonian, Yaqui, and other communities. Journey Colab’s Reciprocity Trust is the only legally binding exception. Colombia 2021 is the only regulatory instrument that has operationalised the deference principle in a drug policy context. Both are reference models for what US state and federal frameworks should require.
Subscribe to Indigenous Knowledge & Benefit Sharing alerts
Receive the Monday 8am HST weekly intelligence digest when new developments are scored for this tab.
We store only the name and email you enter here, and use them only to send this digest. Every email carries an unsubscribe link, which removes the address immediately.